Cephagenix

Cephagenix is a Danish medical technology developer that focuses on identifying and developing new effective therapies for migraine. The company concentrates on identifying and developing selective inhibitors of ATP-sensitive potassium channel subtypes expressed in intracranial arteries. Its compounds have demonstrated efficacy in preclinical migraine models, enabling the development of targeted, mechanism-based treatments for migraine patients.